Last reviewed · How we verify
TP-03
TP-03 is a monoclonal antibody targeting the CD40 receptor.
TP-03 is a monoclonal antibody targeting the CD40 receptor. Used for Dry eye disease.
At a glance
| Generic name | TP-03 |
|---|---|
| Sponsor | Tarsus Pharmaceuticals, Inc. |
| Drug class | monoclonal antibody |
| Target | CD40 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
By binding to CD40, TP-03 is thought to modulate the immune response and potentially treat various inflammatory conditions.
Approved indications
- Dry eye disease
Common side effects
- Conjunctival inflammation
Key clinical trials
- Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD (PHASE2)
- Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study (PHASE3)
- A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects (PHASE1)
- Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex (PHASE2)
- Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (PHASE2, PHASE3)
- Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TP-03 CI brief — competitive landscape report
- TP-03 updates RSS · CI watch RSS
- Tarsus Pharmaceuticals, Inc. portfolio CI